Management of Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration With Anti–Vascular Endothelial Growth Factor Monotherapy – Corrected Proof

Purpose: To report the visual and anatomic outcomes of anti–vascular endothelial growth factor (VEGF) monotherapy in the management of marked submacular hemorrhage secondary to neovascular age-related macular degeneration (AMD).Design: Retrospective, interventional, consecutive case series.Methods: Nineteen eyes of 18 patients with neovascular AMD and fovea involving submacular hemorrhage comprising greater than 50% of the lesion area were treated with anti-VEGF monotherapy. Main outcome measures included mean visual acuity change from baseline, mean central lesion thickness change from baseline, mean number of injections at 6 months, and adverse events. Snellen visual acuity was converted to approximate ETDRS letter score for the purpose of (Read more...)

Full Story →